Strand Therapeutics
BiotechSeries BRisk Assessment
Strand Therapeutics is healthy across all dimensions. Minimal headcount change, reasonable Glassdoor metrics, and strong CEO approval. No signals of concern.
Signal Dimensions
GD Rating
3.4
CEO Approval
83%
Business Outlook
68%
Review Trend
Stable
Glassdoor rating at 3.4 is below average but CEO approval strong at 83%. Mixed but stable.
Last Filing
Dec 2025
Auditor Changes
0
Director Changes
0
Overdue Filings
0
Filings current.
Last Raise
Series B
Time Since Raise
7 months
Funding Stage
Early Growth
Burn Indicator
Low
Well-funded. No burn concerns.
Competitor Raises
1
SoV Trend
Stable
Talent Outflow
Low
Sector Growth
9%
Strong niche position in therapeutics.
Peak HC
138
Current HC
135
HC Decline
-2%
Open Roles
0
Workforce stable. 2% decline is negligible.
Articles (12mo)
4
Avg Tone
+1.0
Days w/ Coverage
3
Sentiment
Positive
Limited but positive media presence.
Score Drivers
No risk drivers detected. All signals within healthy parameters.
Confidence: HIGH · 6 of 6 signals active
Recommended Actions
Routine monitoring recommended. No escalation required.